

REFERENCES for 2004P-0349/CP-1

1. Statement of Karen Midthun, M.D., Director, Office of Vaccine Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, U.S. Department of Health and Human Services, before the Committee on Government Reform, United States House of Representatives, December 10, 2002.
2. Ball, L.K., Ball, R., & Pratt, R.D. (2001). Review Article: An Assessment of Thimerosal Use in Childhood Vaccines, *Pediatrics*, 107, 1147-1154.
3. Joint Statement (concerning Thimerosal) of the American Academy of Pediatrics (AAP) and the U.S. Public Health Service (PHS), July 7, 1999; and Joint Statement Concerning Removal of Thimerosal from Vaccines of the American Academy of Family Physicians (AAFP), the American Academy of Pediatrics (AAP), the Advisory Committee on Immunization Practices (ACIP), and the U.S. Public Health Service (PHS), June 22, 2000.
4. Centers for Disease Control and Prevention (2003). Prevention and Control of Influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP), *MMWR*, April 25, 2003, 52(RR-8), 1-36.
5. Centers for Disease Control and Prevention (2006). Prevention and Control of Influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP), *MMWR*, July 28, 2006, 55(RR-10), 1-42.
6. U.S. Environmental Protection Agency (1992), Revised (2000). Mercury Compounds: Hazard Summary, *Technology Transfer Network Air Toxics Website*, <http://www.epa.gov/ttn/atw/hlthef/mercury.html>.
7. Thimerosal in Vaccines, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, <http://www.fda.gov/cber/vaccine/thimerosal/htm>.
8. Mercury in Plasma-Derived Products, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, <http://www.fda.gov/cber/blood/mercplasma.htm>
9. IOM (Institute of Medicine), (2001). Thimerosal-containing vaccines and neurodevelopmental disorders, Washington, DC: *National Academy Press*.
10. IOM (Institute of Medicine), (2004). Immunization Safety Review: Vaccines and Autism. Washington, DC: *National Academy Press*,(Executive Summary) (emphasis added).
11. Hviid, A., Stellfeld, M., Wohlfahrt, J., and Melbye, M. (2003). Association Between Thimerosal-Containing Vaccine and Autism, *JAMA*, 290, 1763-1766.

12. Verstraeten, T., Davis, R.I., DeStefano, F., Lieu, T.A., Rhodes, P.H., Black, S.B., et al. (2003). Safety of Thimerosal-Containing Vaccines: A Two-Phased Study of Computerized Health Maintenance Organization Databases, *Pediatrics*, *112*(5), 1039-1048.
13. Andrews, N., Miller, E., Grant, A, Stowe, J., Osborne, V., & Taylor, B. (2004). *Pediatrics*, *114*, 584-591.
14. Madsen, K.M., Lauritsen, M.B., Pedersen, C.B., Thorsen, P., Plesner, A-M., Andersen, P.H., et al. (2003). Thimerosal and the Occurrence of Autism: Negative Ecological Evidence From Danish Population-Based Data, *Pediatrics*, *112*, 604-606.
15. Stehr-Green, P., Tull, P., Stellfeld, M., Mortenson, P-B., Simpson, D. (2003). Autism and Thimerosal-Containing Vaccines: Lack of Consistent Evidence for an Association, *American Journal of Preventive Medicine*, *25*(2), 101-106.
16. Geier, D.A., & Geier, M.R. (2003). An assessment of the impact of thimerosal on childhood neurodevelopmental disorders, *Pediatric Rehabilitation*, *6*(2), 97-102.
17. Geier, D.A., & Geier, M.R. (2004). A comparative evaluation of the effects of MMR immunization and mercury doses from thimerosal-containing childhood vaccines on the population prevalence of autism, *Med Sci Monit*, *10*(3), 133-139.
18. Geier, M.R., & Geier, D.A. (2003). Neurodevelopmental Disorders after Thimerosal-Containing Vaccines: A Brief Communication, *Society for Experimental Biology and Medicine*, 660-664.
19. Geier, M.R., & Geier, D.A. (2003). Thimerosal in Childhood Vaccines, Neurodevelopmental Disorders, and Heart Disease in the United States, *Journal of American Physicians and Surgeons*, *8*(1), 6-11.
20. Geier, D., Geier, M. (2004). From Epidemiology, Clinical Medicine, Molecular Biology, and Atoms, to Politics: A Review of the Relationship Between Thimerosal and Autism. *Submission to the Institute of Medicine, Immunization Safety Review Committee*. Washington, D.C.
21. Fombonne, E., Zakarian, R., Bennett, A., Meng, L., & McLean-Heywood, D. (2006). Pervasive Developmental Disorders in Montreal, Quebec, Canada: Prevalence and Links With Immunizations, *Pediatrics*, *118*(1), e139-e150.
22. Parker, S. K., Schwartz, B., Todd, J., & Pickering, L.K. (2004). Thimerosal-Containing Vaccines and Autistic Spectrum Disorder: A Critical Review of Published Original Data, *Pediatrics*, *114*(3), 793-804.

23. Plotkin, S.A., & Orenstein, W.A. (2004). *Vaccines, fourth edition*, Saunders, Philadelphia, Pa.
24. Centers for Disease Control and Prevention (2003). Update: Influenza Activity --- United States, 2003--04 Season, *MMWR Weekly, December 12, 2003, 52(49)*, 1197-1202.
25. Sax, N.I. (1984). *Dangerous Properties of Industrial Materials*, Van Nostrand Reinhold Company: New York, Cincinnati, Toronto, London, Melbourne.
26. Clarkson, T.W. (1972). The Pharmacology of Mercury Compounds, *Annual Review of Pharmacology, 12*, 375-406.
27. Fitzhugh, O.G., Nelson, A.A., Laug, E.P., & Kunze, F.M. (1950). Chronic Oral Toxicities of Mercuri-Phenyl and Mercuric Salts, *Archives of Industrial Hygiene and Occupational Medicine, 2*, 433-442.
28. Hayes, Jr., W.J. (1982). *Pesticides Studied in Man*. Williams & Wilkins: Baltimore/London.
29. Labeling of Visine L.R.® showing directions for use for children over 6 years of age and adults, and for children under 6 years of age to consult a doctor.
30. Labeling of FML® Ointment showing directions for use (dosage and administration).
31. Golightly, L.K., Smolinske, S.S., Bennett, M.L., Sutherland, III., E.W., & Rumack, B.H. (1988). Pharmaceutical Excipients: Adverse Effects Associated with Inactive Ingredients in Drug Products (Part I), *Medical Toxicology, 3*, 128-165.
32. Study submitted to an approved NDA: Viroptic (Trifluridine Ophthalmic Solution).
33. Recommended dose in each eye: Blephamide, Ophthalmic Ointment, USP; and Cortisporin® Ophthalmic Suspension Sterile.
34. Mercury in Drug and Biologic Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, <http://www.fda.gov/cder/fdama/mercury300.htm> (concentration of Thimerosal in nasal solutions and sprays, and otic products).
35. Leong, C.C.W., Syed, N.I., & Lorscheider, F.L. (2001). Retrograde degeneration of neurite membrane structural integrity of nerve growth cones following *in vitro* exposure to mercury, *NeuroReport, 12 (4)*, 733-737.
36. Baskin, D.S., Ngo, H., & Didenko, V.V. (2003). Thimerosal Induces DNA Breaks, Caspase-3 Activation, Membrane Damage, and Cell Death in Cultured Human Neurons and Fibroblasts, *Toxicological Sciences, 74*, 361-368.

37. Makani, S., Gollapudi, S., Yel, L., Chiplunkar, S., & Gupta, S. (2002). Biochemical and molecular basis of thimerosal-induced apoptosis in T cells: a major role of mitochondrial pathway, *Genes and Immunity*, 3(5), 270-278.

38. Waly, M., Olteanu, H., Banerjee, R., Choi, S-W, Mason, J.B., Parker, B.S., et al. (2004). IMMEDIATE COMMUNICATION: Activation of methionine synthase by insulin-like growth factor-1 and dopamine: a target for neurodevelopmental toxins and thimerosal, *Molecular Psychiatry*, 1-13.

39. Chao, E. S-E, Gierthy, J.F., & Frenkel, G.D. (1984). A Comparative Study of the Effects of Mercury Compounds on Cell Viability and Nucleic Acid Synthesis in HeLa Cells, *Biochemical Pharmacology*, 33, 1941-1945.

40. Pierce, R.H., Franklin, C.C., Campbell, J.S., Tonge, R.P., Chen, W., Fausto, N., et al. (2002). Cell culture model for acetaminophen-induced hepatocyte death *in vivo*, *Biochemical Pharmacology*, 64, 413-424.

41. Bajt, M.L., Knight, T.R., Lemasters, J.J., & Jaeschke, H. (2004). Acetaminophen-Induced Oxidant Stress and Cell Injury in Cultured Mouse Hepatocytes: Protection by N-Acetyl Cysteine, *Toxicological Sciences*, 80(2), 343-349.

42. Hornig, M., Chian, D., & Lipkin, W.I. (2004) Neurotoxic effects of postnatal thimerosal are mouse strain dependent, *Molecular Psychiatry*, 1-13.

43. Havarinasab, S., Lambertsson, L., Qvarnstrom, J., & Hultman, P. (2004). Dose-response study of thimerosal-induced murine systemic autoimmunity, *Toxicology and Applied Pharmacology*, 194, 169-179.

44. Critical Path Initiative (69 FR 21839, April 22, 2004)

45. California Department of Developmental Services (2003). Autistic Spectrum Disorders: Changes in The California Caseload: An Update: 1999 Through 2002. Sacramento, California.

46. Autism A.L.A.R.M. (2004). Fact Sheet, Department of Health and Human Services, Centers for Disease Control and Prevention, American Academy of Pediatrics, & Medical Home Initiatives. <http://www.medicalhomeinfo.org/health/Autism%20downloads/Autism/Alarm.pdf>.

47. California Environmental Protection Agency (2004). Response to the Petition of Bayer Corporation for Clarification of the Proposition 65 Listing of "Mercury and Mercury Compounds" As Chemicals Known to Cause Reproductive Toxicity, Sacramento, California.

48. Bradstreet, J., Geier, D.A., Kartzinel, J.J., Adams, J.B., & Geier, M.R. (2003). A Case-Control Study of Mercury Burden in Children with Autistic Spectrum Disorders, *Journal of American Physicians and Surgeons*, 8(3), 76-79.

49. Holmes, A.S., Blaxill, M.F., & Haley, B.E. (2003). Reduced Levels of Mercury in First Baby Haircuts of Autistic Children, *International Journal of Toxicology*, 22, 277-285.
50. Stetler, H.C., Garbe, P.L., Dwyer, D.M., Facklam, R.R., Orenstein, W.A., West, G.R., et al. (1985). Outbreaks of Group A Streptococcal Abscesses Following Diphtheria-Tetanus Toxoid-Pertussis Vaccination, *Pediatrics*, 75 (2), 299-303.
51. USP (2006). Antimicrobial Effectiveness Testing. In 2006 USPC Official 8/1/06 - 4/30/07 (chap. 51). Retrieved December 19, 2006, from http://www.uspnf.com/uspnf/pub/data/v29242/usp29nf24s_c51.xml.
52. Gasset, A.R., Itoi, M., Ishii, Y., & Ramer, R.M. (1975). Teratogenicities of Ophthalmic Drugs. II. Teratogenicities and Tissue Accumulation of Thimerosal, *Archives of Ophthalmology*, 93, 52-55.
53. Redwood, L., Bernard, S., & Brown, D. (2001). Predicted Mercury Concentrations in Hair From Infant Immunizations: Cause for Concern, *NeuroToxicology*, 22, 691-697.
54. Slikker, W. (2000). Developmental Neurotoxicology of Therapeutics: Survey of Novel Recent Findings, *NeuroToxicology*, 21, page 250.
55. Stajich, G.V., Lopez, G.P., Harry, S.W., & Sexson, W.R. (2000). Iatrogenic exposure to mercury after hepatitis B vaccination in preterm infants, *Pediatrics*, 136, 679-681.
56. Sager, P. (2004). NIAID Studies on Thimerosal (slides), presented to the Institute of Medicine, February 9, 2004.
57. Burbacher, T., & Shen, D. (2004). Comparative Toxicokinetics of Methyl mercury (MeHg) and Thimerosal in Infant *Macca fascicularis* (slides), presented to the Institute of Medicine, February 9, 2004.
58. Nelson, E.A., & Gottshall, R.Y. (1967). Enhanced Toxicity for Mice of Pertussis Vaccines When Preserved with Merthiolate, *Applied Microbiology*, 15(3), 590-593.
59. Heyworth, M.F., & Truelove, S.C. (1979). Problems Associated With The Use Of Merthiolate As A Preservative In Anti-Lymphocytic Globulin, *Toxicology*, 12, 325-333.
60. Förström, L., Hannuksela, M., Kousa, M., & Lehmuskallio, E. (1980). Merthiolate hypersensitivity and vaccination, *Contact Dermatitis*, 6, 241-245.
61. Kravchenko, A.T., Dzagurov, S.G., & Chervonskaia, G.P. (2003). Abstract (article in Russian) Evaluation of the toxic action of prophylactic and therapeutic preparations on cell cultures. III. The detection of toxic properties in medical biological preparations by the degree of cell damage in the L132 continuous cell line, *Zh Mikrobiol Epidemiol Immunobiol*, 3, 87-92.

62. Winship, K.A. (1986). Organic mercury compounds and their toxicity, *Adverse Drug Reaction Acute Poisoning Review*, 3, 141-180.

63. Cox, N.H., & Forsyth, A. (1988). Thimerosal allergy and vaccination reactions, *Contact Dermatitis*, 18, 229-233.

64. Seal, D., Ficker, L., Wright, P., & Andrews, V. (1991). The case against thimerosal, *The Lancet*, 338, 315-316.

65. van't Veen, A-J. (2001). Vaccines Without Thiomersal: Why So Necessary, Why So Long Coming?, *Drugs*, 61(5), 565-572.

66. Schumm, W.R., Reppert, E.J., Jurich, A.P., Bollman, S.R., Webb, F.J., Castelo, C.S., et al. (2002). Self-Reported Changes In Subjective Health And Anthrax Vaccination As Reported By Over 900 Persian Gulf Era Veterans, *Psychological Reports*, 90, 639-653.

67. Tryphonas, L., & Nielsen, N.O. (1973). Pathology of Chronic Alkylmercurial Poisoning in Swine, *American Journal of Veterinary Research*, 34(3), 379-392.

68. Fagan, D.G., Pritchard, J.S., Clarkson, T.W., & Greenwood, M.R. (1977). Organ mercury levels in infants with omphaloceles treated with organic mercurial antiseptic, *Archives of Disease in Childhood*, 52, 962-964.

69. Magos, L., Brown, A.W., Sparrow, S., Bailey, E., Snowden, R.T., & Skipp, W.R. (1985). The comparative toxicology of ethyl- and methylmercury, *Archives of Toxicology*, 57, 260-267.

70. Ashwood, P., Anthony, A., Pellicer, A.A., Torrente, F., Walker-Smith, J.A., & Wakefield, A.J. (2003). Intestinal Lymphocyte Populations in Children with Regressive Autism: Evidence for Extensive Mucosal Immunopathology, *Journal of Clinical Immunology*, 23(6), 504-517.

71. McGinnis, W.R. (2001). Mercury and Autistic Gut Disease, *Environmental Health Perspectives*, 109(7), A303-A304.

72. Megson, M.N. (2000). Is autism a G-alpha protein defect reversible with natural vitamin A?, *Medical Hypotheses*, 54(6), 979-983.

73. In Re Cincinnati Radiation Litigation, 874 F. Supp. 796 (S.D. Ohio, 1995).

74. Albright v. Oliver, 510 U.S. 266 (1994).

75. Schmerber v. California, 384 U.S. 757 (1966).